Clinical Trial Update: Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib plus gemcitabine hydrochloride in relapsed or refractory Hodgkin lymphoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Gemzar (gemcitabine)
• Velcade (bortezomib)

Snippet

Sponsor: University of Rochester | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-28